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Two antigenically distinct lineages of influenza B viruses have
circulated globally since 1985. However, licensed trivalent
seasonal influenza vaccines contain antigens from only a
single influenza B virus and thus provide limited immunity
against circulating influenza B strains of the lineage not
present in the vaccine. In recent years, predictions about
which B lineage will predominate in an upcoming influenza
season have been no better than chance alone, correct in
only 5 of the 10 seasons from 2001 to 2011. Consequently,
seasonal influenza vaccines could be improved by inclusion of
influenza B strains of both lineages. The resulting quadrivalent
influenza vaccines would allow influenza vaccination
campaigns to respond more effectively to current global
influenza epidemiology. Manufacturing capacity for seasonal
influenza vaccines has increased sufficiently to supply
quadrivalent influenza vaccines, and methods to identify the
influenza B strains to include in such vaccines are in place.
Multiple manufacturers have initiated clinical studies of
quadrivalent influenza vaccines. Data from those studies,
taken together with epidemiologic data regarding the burden
of disease caused by influenza B infections, will determine
the safety, effectiveness, and benefit of utilizing quadrivalent
vaccines for the prevention of seasonal influenza disease.
Introduction
Influenza A/H1N1, A/H3N2 and B viruses have circulated and
caused disease in humans on a global basis since 1977.
1 Accord-
ingly, licensed seasonal influenza vaccines have contained three
strains, one from each A subtype and one type B virus. Because
new variant strains of each type/subtype continually evolve, the
specific strains to be included in seasonal influenza vaccines are
chosen based on a prediction of the strains likely to circulate in
the upcoming influenza season.
1 Since 1985, two antigenically
distinct lineages of influenza B viruses have circulated globally.
2
However, as only one lineage can be selected for inclusion in
current trivalent influenza vaccines, the vaccines have provided
limited immunity against strains of the other lineage.
3,4 Addition-
ally, in 5 of the 10 influenza seasons between 2001–2002 and
2010–2011, the predominant circulating influenza B lineage was
different from that chosen for the vaccine.
5,6 Consequently,
influenza vaccination campaigns have had limited effectiveness
against influenza B epidemics during seasons in which a signi-
ficant proportion of the disease was caused by opposite-lineage
influenza B strains. This reduced effectiveness in such seasons
could be avoided if seasonal influenza vaccines included four
strains, one strain from each B lineage in addition to A/H1N1
and A/H3N2 strains. The current review describes the burden of
disease caused by influenza B infection, evaluates the impact of
two distinct circulating influenza B lineages, and provides data
supporting the feasibility of the development and widespread
adoption of quadrivalent influenza vaccines.
Influenza B Accounts for a Significant Proportion of
the Overall Burden of Influenza
Both influenza A and B are orthomyxoviruses that cause annual
epidemics in humans on a global scale. Influenza B predominantly
circulates in human populations, in contrast to influenza A, which
circulates in multiple animal species as well as in humans. Like
influenza A, novel variant strains of influenza B continually
emerge due to antigenic drift. In recent years, influenza B viruses
have evolved more slowly than A/H3N2 viruses, as evidenced by a
lower rate of nucleotide substitution, estimated at 0.14  10
-3 to
3.32  10
-3 substitutions/site/year for influenza B vs. 2.68  10
-3
to 12.50  10
-3 for influenza A/H3N2.
7,8 The likelihood that
substitutions result in amino acid changes is also lower for B
viruses compared with A/H3N2 viruses.
7 However, there is
frequent segment reassortment between influenza B viruses,
which is often the mechanism by which new dominant B viruses
emerge.
7
The incidence of influenza B can vary dramatically between
influenza seasons. According to data from the US. Centers for
Disease Control and Prevention (CDC), from 2001–2002
through 2010–2011 (excluding the 2009–2010 pandemic), influ-
enza B was responsible for , 1% to 44% of influenza-positive
samples submitted by participating laboratories (Fig.1A). On
average, 24% of influenza samples during this period were posi-
tive for influenza B. European surveillance data from the same
seasons was similar, with influenza B being responsible for 1%
to 60% of influenza-positive samples and a season average of
23% (Fig.1B). These data are consistent with a Dutch study that
systematically examined cases of influenza-like illness from 1992–
1993 through 2006–2007 and found the proportion of influenza
cases caused by influenza B to range from 0% to 82% by season,
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with a season average of 29%.
9 Influenza B was responsible
for more than 30% of cases in 7 of the 15 seasons. Similarly, in
data from Finland from 1980 to 1999, influenza B accounted
for 20% of influenza cases among children ,17 y of age, and
was the predominant cause of influenza illness in 5 of the
20 seasons.
10
Studies of severe influenza disease in the US have shown
that influenza B causes significant morbidity and mortality. For
influenza-attributable respiratory- and circulatory-related hospita-
lizations in all ages from 1979–1980 through 2000–2001, the
estimated hospitalization rate during seasons dominated by
influenza B was 81.4 hospitalizations per 100,000, which
approached the hospitalization rate observed in A/H3N2-
predominant seasons (99.0 per 100,000) and was greater than
that observed in A/H1N1-predominant seasons (55.9 per
100,000).
11 Between 1990–1991 and 1998–1999, influenza B
Figure1. Influenza B circulation as a proportion of circulating influenza strains: US and European data for 2001 to 2011. US data (A) were extracted from
cumulative data reported in the final CDC weekly influenza surveillance report for each season (available at www.cdc.gov/flu/weekly/pastreports.htm).
Data for 2008–2009 represent cumulative data through April 18, 2009. EU data (B) were extracted from cumulative Euroflu sentinel site data reported in
the final weekly influenza surveillance bulletin for each season beginning with the 2003–2004 season (available at www.euroflu.org/cgi-files/bulletin_v2.
cgi). Because Euroflu bulletins issued before 2003–2004 do not provide cumulative season data, data presented for the 2001–2002 and 2002–2003
influenza seasons were extracted from the final cumulative European Influenza Surveillance Scheme report issued in 2007 (available at www.euroflu.org/
documents/eiss_annual_report_2006-2007.pdf).
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was estimated to account for 15% of all influenza-attributable
respiratory- and circulatory-related deaths in the US. The
estimated average annual deaths due to influenza B (5255) was
lower than the number attributed to A/H3N2 (28,940), but
higher than the number attributed to A/H1N1 (1960).
12
Although influenza B causes disease in all age groups, its
incidence relative to influenza A appears to be highest among
older children and young adults. In studies that described influ-
enza illness among children and adults, the proportion of illnesses
caused by influenza B relative to influenza A was highest for
individuals 5 to 29 y of age
13 and 2 to 39 y of age.
14 A study
describing absenteeism among Japanese schoolchildren for the
24 y between 1984 and 2007 demonstrated that influenza B was
responsible for the largest outbreaks, and outbreaks were observed
even during seasons in which many children were vaccinated.
15
Multiple studies of medically-attended influenza in children have
demonstrated that children with influenza B illness are older than
those with influenza A.
10,16-20 Furthermore, while influenza B
causes mortality in all age groups, it appears to be a dispropor-
tionate cause of pediatric influenza deaths. The CDC made US
pediatric influenza deaths reportable beginning with the 2004–
2005 season. From 2004–2005 through 2010–2011, with the
exception of the 2009–2010 pandemic, influenza B was
responsible for 22–44% of reported influenza deaths in children
0–18 y of age each season (Fig.2). Overall, during this period,
influenza B was responsible for 34% of reported pediatric
influenza deaths. Thompson et al. also estimated that influenza
B was a disproportionate cause of influenza deaths among
children. Influenza B was responsible for 27% and 26% of
influenza-attributable respiratory- and circulatory-related deaths
among infants younger than 12 mo of age and children 1–4yo f
age, respectively, as compared with 17%, 12%, and 15% among
individuals 5–49 y of age, 50–64 y of age, and 65 y of age and
older, respectively.
12
Medically-attended illnesses in both children and adults due to
influenza A and B are generally similar in regards to symptoms,
severity, and rates of influenza-related complications.
10,16-25 The
principal differences observed across studies are that influenza B
disease in children is more commonly associated with myalgia,
myositis, and leukopenia.
10,17,19,22,23 Three studies found that
influenza B was less commonly associated with rhinorrhea in
children.
10,22,23 One study noted a shorter duration of illness in
children with influenza B,
16 but in other studies duration was
similar.
17,18 In adults, the duration of influenza A and B illness
was similar.
24,25
One Virus, Two Lineages
Although influenza B viruses are classified as a single influenza
type, B viruses can be categorized into two antigenically distinct
phylogenetic lineages, B/Victoria/02/87-like and B/Yamagata/16/
88-like, based on divergence in the HA1 domain of the viral
hemagglutinin gene (Fig.3). Before 1985, there was a single
lineage of influenza B in global circulation. This lineage was the
precursor to the subsequent Yamagata lineage.
2 The Victoria
lineage appears to have emerged from a minor lineage of B viruses
Figure2. Proportion of US pediatric influenza deaths by viral type (2004 to 2011, excluding 2009–2010 pandemic). Values in columns represent the
number of deaths in each category for each season. Data for the 2004–2005 through 2008–2009 seasons were obtained via personal communication
with the CDC. Pediatric influenza deaths became reportable in 2004–2005; as a result, comparable data are not available prior to 2004–2005. Data for the
2010–2011 season was obtained from the CDC 2010–2011 Influenza Season Summary (available at www.cdc.gov/flu/weekly/pastreports.htm).
www.landesbioscience.com Human Vaccines & Immunotherapeutics 83© 2012 Landes Bioscience.
Do not distribute.
in China by 1975 but was not isolated outside of China until
1985.
26 Following the global detection of Victoria-like strains in
1985, the Victoria lineage dominated global circulation from
1987 to 1989, followed by Yamagata dominance in the 1990s and
subsequent re-emergence of the Victoria lineage in 2001–2002.
From 2001–2002 to the present, both lineages have co-circulated
each season at varying levels (Fig.4).
The pattern of varying dominance of the two influenza B
lineages is likely driven by lineage-specific immunity in the
population, with one lineage predominating until accumulated
immunity to that lineage results in increased relative susceptibi-
lity to and spread of the other lineage.
7 A serologic study of
European children 0 to 7 y of age, almost none of whom had
been previously vaccinated against influenza, demonstrated that
children accumulated natural immunity to influenza B more
slowly than to influenza A.
27 This observation likely explains the
increased incidence of influenza B illness relative to influenza A
among older children and young adults. An important obser-
vation by Bodewes et al. was that antibody responses to influenza
B infection in children were lineage-specific, with no cross-
reactivity between lineages. A similar pattern of limited cross-
reactivity occurs in response to influenza vaccination. For trivalent
inactivated influenza vaccines (TIV), antibody responses to the
lineage not contained in the vaccine are reduced in adults and
negligible in children.
4 In recent randomized, placebo-controlled
efficacy studies of TIV in younger adults, efficacy against
opposite-lineage B strains has been variable, ranging from 22%
to 52%,
28,29 which is lower than the observed efficacy against
vaccine-matched strains of 78%.
29 With trivalent live attenuated
influenza vaccine in children, 31% efficacy has been observed
Figure3. Evolution of two antigenically distinct lineages of influenza B (1970–2006). Phylogenetic tree of the influenza B virus HA1 domain based on 214
sequences sampled annually between 1970 and 2006. Data for the B/Victoria/02/87-like and B/Yamagata/16/88-like lineages are shown. Representative
vaccine strains are also shown. Adapted with permission from Chen R. Holmes E.C. The evolutionary dynamics of human influenza
B virus.
7
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against opposite-lineage influenza B strains, which is lower than
the 86% efficacy against vaccine-matched B strains.
3
Inability to Predict Which Influenza B Lineage
Will Circulate
In recent years, predictions of the predominant influenza B
lineage have been no better than chance alone. In 5 of the
10 influenza seasons in the US from 2001–2002 through 2010–
2011, the predominant circulating influenza B lineage was
different from that contained in the vaccine (Fig.4A). Overall,
an estimated 46% of influenza B samples during this period were
influenza B strains of the lineage not included in the vaccine.
Similarly, in Europe from 2003–2004 through 2010–2011 (the
seasons for which data are available), the predominant lineage
differed from that contained in the vaccine in 4 of 8 seasons
Figure4. Influenza B circulation by lineage: US and European data for 2001 to 2011. Data were obtained as reported for Figure1. US data are
represented in panel A (A) and European data are represented in panel B (B). The influenza B lineage (Victoria or Yamagata) recommended for inclusion
in the trivalent vaccine is shown on the x-axis for each season. EU data regarding the proportion of B viruses by lineage were not available for the
2001–2002 and 2002–2003 influenza seasons.
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(Fig.4B), and an estimated 58% of influenza B samples were of
the lineage not included in the vaccine. Because inclusion of the
incorrect influenza B lineage in trivalent vaccines provides
suboptimal protection against circulating opposite-lineage strains,
inaccurate prediction of the predominant influenza B lineage
leaves many vaccinated individuals with suboptimal protection
from influenza B disease.
The magnitude of the problem created by mismatch between
circulating influenza B strains and the influenza B lineage
contained in the vaccine varies by season. The most significant
recent examples occurred during the 2005–2006 and 2007–2008
seasons. In 2005–2006, the influenza B component of the
northern hemisphere influenza vaccine was of the B/Yamagata
lineage, but 81–91% of the circulating influenza B viruses
antigenically characterized in the US and Europe were of the
B/Victoria lineage, and influenza B was found in 34–60% of all
samples (Figs.1 and 4). Similarly, in 2007–2008, the influenza B
component of the vaccine was of the B/Victoria lineage, but 98–
99% of the circulating influenza B viruses characterized in the US
and Europe belonged to the B/Yamagata lineage, and influenza
B was found in 29–39% of all samples (Fig.1 and 4). In other
seasons, the magnitude of the problem was less, such as when the
vaccine component was a good match to circulating strains (e.g.,
2002–2003 and 2010–2011) or when influenza B illness was less
common (e.g., 2003–2004 and 2009–2010).
Potential Benefits of Quadrivalent Influenza Vaccines
Based on the demonstrated burden of influenza B, the limited
cross-protection between the two influenza B lineages, and the
inability to accurately predict which influenza B lineage will
circulate, it is clear that seasonal influenza vaccines could be
improved by the inclusion of influenza B strains from both
lineages. The rationale for the shift from trivalent to quadrivalent
influenza vaccines is similar to that for the 1977 transition from
a bivalent (A/H3N2 and B) vaccine to a trivalent (A/H1N1,
A/H3N2, B) vaccine, which was based on the lack of cross-
protection between A/H3N2 and A/H1N1. The inclusion of
both influenza B lineages would provide a direct benefit to
vaccine recipients whenever a large number of circulating influ-
enza B viruses does not match the lineage chosen for trivalent
vaccines, either because the lineage prediction was incorrect or
because both lineages co-circulated to a significant degree.
Moreover, in seasons in which influenza B circulation is minimal
or B viruses are well matched to the trivalent vaccine strain,
vaccination with a quadrivalent influenza vaccine would still
provide benefit to the individual by increasing immunity to
both lineages of influenza B, with potential clinical benefit in
subsequent seasons.
30 Accumulated immunity may be more
relevant for influenza B than for influenza A because antigenic
drift is more limited with influenza B viruses. From a public
health perspective, if quadrivalent vaccines led to fewer mis-
matched seasonal vaccine campaigns, the public’s confidence and
acceptance of influenza vaccination might also be enhanced.
31
The CDC recently conducted an analysis to quantify the
potential public health impact of a quadrivalent influenza vaccine
strategy relative to dependence on trivalent vaccines.
32 Based on
the available input data and the assumption that quadrivalent
vaccine production would not decrease influenza vaccine supply,
the analysis suggested that use of quadrivalent vaccines in the
US during the 2001–2008 seasons would have been beneficial in
each season, cumulatively resulting in approximately 2.1 million
fewer cases of influenza, 20,000 fewer hospitalizations, and 1,200
fewer deaths.
Optimal target populations for quadrivalent influenza vaccines
are a subject of ongoing discussion (FDA VRBPAC 2007, 2009,
2011).
33-35 The primary benefit of a quadrivalent vaccine is in
eliminating the risk that the incorrect B lineage is selected for
inclusion in the vaccine. The clinical benefit is likely to be highest
among children and young adults because of the increased
incidence of influenza B disease in these age groups, and studies
in children with live attenuated and inactivated influenza vaccines
have shown little to no cross-protection against opposite-lineage
strains following vaccination. However, cross-lineage protection
from vaccination is also reduced in adults, and influenza B
accounts for a significant proportion of influenza-related morbi-
dity and mortality in all age groups, even among older adults.
Because individuals of all ages would be expected to benefit from
quadrivalent influenza vaccines, there is a strong rationale for
providing quadrivalent influenza vaccines to all indicated age
groups, as long as the incremental cost relative to trivalent
vaccines is not excessive.
Path Forward for Quadrivalent Vaccines
Presumably, quadrivalent influenza vaccines would be very similar
to currently licensed trivalent vaccines in regards to manufactur-
ing processes, as well as vaccine excipients, dose, and administra-
tion. The only expected difference would be the inclusion of four
influenza vaccine strains (A/H1N1, A/H3N2, and B strains of
both lineages). Influenza B strains to be included in the vaccines
could be chosen through the current processes for strain selection.
In fact, the World Health Organization (WHO) recommenda-
tions for the 2011–2012 northern hemisphere seasonal influenza
vaccine formulation already identify candidate vaccine strains
from both influenza B lineages.
36
Multiple manufacturers have initiated clinical studies to
evaluate the immunogenicity and safety of quadrivalent influenza
vaccines relative to trivalent vaccines in children and adults.
33,37-44
In the past, efforts to advance quadrivalent influenza vaccines
were complicated by concerns about influenza vaccine manufac-
turing capacity, but now capacity has increased to the point that
introduction of quadrivalent vaccines should not impact the
overall supply of influenza vaccines.
32 In 2006, the WHO
estimated that global manufacturing capacity for seasonal trivalent
influenza vaccine was 347 million doses.
45 In 2009, capacity
increased to 876 million doses due to investments by manufac-
turers and governments. However, only 66% of the available
global capacity in 2009 was utilized for production of 2008–2009
seasonal influenza vaccines.
46 Production of quadrivalent vaccines
could help maintain the current global manufacturing capacity,
which would also enhance pandemic preparedness since the
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capacity could be redirected to manufacture monovalent
pandemic doses.
Widespread utilization of quadrivalent influenza vaccines will
require confirmation that quadrivalent influenza vaccines pro-
duce immune responses in children and adults comparable to
those observed with trivalent seasonal influenza vaccines. Addi-
tionally, clinical studies must confirm that quadrivalent influenza
vaccines have an acceptable safety profile in children and adults.
Cost-effectiveness analyses comparing quadrivalent and trivalent
vaccines will also be required if there is a significant incremental
cost associated with quadrivalent vaccines. Lastly, acceptance of
quadrivalent influenza vaccines by providers, payers, and the
general public will require education regarding the benefits and
safety of vaccines containing the additional strain.
Conclusion
Quadrivalent formulations represent a next logical step for sea-
sonal influenza vaccines. Because 2 antigenically distinct influenza
B lineages have been circulating since 1985 and the predominant
influenza B lineage has been unpredictable in recent years,
quadrivalent vaccines would more accurately reflect the current
epidemiology of influenza and would allow vaccination cam-
paigns to more effectively protect their target populations.
Multiple manufacturers have initiated clinical studies of quadri-
valent influenza vaccines. Data from those studies, as well as
epidemiologic data regarding the burden of influenza B infections,
will determine the safety, effectiveness, and benefit of utilizing
quadrivalent vaccines for the prevention of seasonal influenza
disease.
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